×

Do you want to link to this External Site and leave Amgen.com?

YOU ARE NOW LEAVING AMGEN'S WEB SITE. Amgen takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

×

Do you want to link to this External Site and leave Amgen.com?

YOU ARE NOW LEAVING AMGEN'S WEB SITE. Amgen takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

×

Do you want to link to this External Site and leave Amgen.com?

YOU ARE NOW LEAVING AMGEN'S WEB SITE. Amgen takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

×

Do you want to link to this External Site and leave Amgen.com?

YOU ARE NOW LEAVING AMGEN'S WEB SITE. Amgen takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

×

 

Amgen Speaks Out Against CA Prop. 61


Election Day is November 8. Voting is your right as an American citizen, and the ultimate expression of your freedom. Consider voting ‘No’ on CA Prop. 61.

At Amgen, our mission is to serve patients. We are focused on helping people with serious diseases by delivering medicines that improve health outcomes and by collaborating on programs and policies to improve our healthcare system.

Improving access to and affordability of medicines requires everyone—from manufacturers to healthcare professionals to insurers to government agencies to healthcare delivery systems — to engage and work together to improve the system. At Amgen, we are engaging in those discussions and are committed to working with others to address challenges and improve short- and long-term health.

In California, we are facing a flawed ballot measure known as Prop. 61, which has the potential to negatively impact our ability to innovate and provide medicines to the patients who need them. That’s why Amgen is joining nearly 200 organizations including the California Medical Association, Veterans of Foreign Wars, and the California Taxpayers Association in opposition to this measure.

Specifically, Prop. 61 would prohibit California state agencies from buying a prescription drug from a manufacturer at any price over the lowest price paid by the United States Department of Veterans Affairs (VA). Every daily newspaper throughout the state is urging voters to oppose Prop. 61 because it’s poorly written, difficult to implement and could actually raise the costs of prescription drugs for the state.

In the state’s Official Voter Guide, the Legislative Analyst Office (LAO) describes "major uncertainties" concerning Prop. 61 - implementation of the initiative could increase prescription drug costs for the VA. In a report to the legislature, the LAO also cautioned that “the measure could raise Department of Health Care Services’ spending on prescription drugs.” It is actually difficult to understand how any state program would benefit from Prop. 61, and ironically, the initiative’s sponsor specifically exempted his own organization from the measure.

Another reason Amgen opposes Prop. 61 is because it could impact our nation’s veterans. The VA has warned that an extension of its confidential contract pricing to other sizable populations, including state governments, could undermine the VA’s ability to obtain favorable drug pricing. They estimated that Prop 61 could increase prescription drug costs by as much as $3.8 billion annually, hurting our nation’s veterans and their families.

You can learn more by visiting www.noprop61.com.

Paid for by Amgen